An observational study in Acute Exacerbation of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca. Completed at 13 sites in China. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2016-06-15.
Sponsored by AstraZeneca · Observational
The purpose of this study is observe clinical practice including glucocorticoids treatment in AECOPD in China.
It is widely recognized that the global social and economic burden of Chronic obstructive pulmonary disease (COPD) is high; affecting an estimated 64 million people worldwide. It was reported the prevalence of COPD in China population over 40 years old is about 8.2% (Zhong Nanshan et al, 2007). According to the report on China Chronic Disease, COPD is the second disease of Disability Adjusted Life Years. The economic burden of COPD is tremendous in China. Cost analysis in 2006 showed that every COPD patient in urban would pay 1732.24 $ on medical cost every year, indirect cost on nurse and traffic is 231.6 $, total cost would account for 40% of average family income in 2006(Chiang CH.,2008).AECOPD is one of most important cause leading to COPD death. Corticosteroid is essential for AECOPD management and recommended by domestic and international guidelines. But it shows that corticosteroid use for treating AECOPD in China is around 70% from market research in big hospitals, and less report about how steroid is used for AECOPD management was published, including distribution, dosage, treatment duration, etc. The healthcare resources utilization for treating AECOPD in China is also unclear.
2,592 studies on the registry are indexed under Lung Diseases, Obstructive; 198 are open to participants now.
This study's enrollment of 5,095 is above the median of 150 across 639 observational studies indexed under Lung Diseases, Obstructive.
Browse Lung Diseases, Obstructive studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
The patient population will be ≥40 years of age, received hospitalization due to AECOPD since Sep, 2013. The patients should be diagnosed by GOLD 2013 as COPD at least 3 months before AECOPD based on treating physician judgment.
Exclusion Criteria:
Percentage of glucocorticoids treatment for AECOPD
Time frame: day 1 to up to 30 days (Hospital discharge)
Percentage of oral /intravenous/ inhaled steroid therapy in patients treated with glucocorticoids, mean dosage, regimen and treatment duration via different administration route in hospital
Time frame: day 1 to up to 30 days (Hospital discharge)
Percentage of antibiotics treatment for AECOPD by clinicians during the hospitalization.
Time frame: day 1 to up to 30 days (Hospital discharge)
Mortality caused by AECOPD and recorded as primary cause of death by clinicians
Time frame: day 1 to up to 30 days (Hospital discharge)
Percentage of antibiotics treatment via different administration route for AECOPD, mean treatment duration via different administration route in hospital
Time frame: day 1 to up to 30 days (Hospital discharge)
Endotracheal intubation rate in treatment of AECOPD
Time frame: day 1 to up to 30 days (Hospital discharge)
Pneumonia rate at the diagnose of AECOPD and in treatment of AECOPD
Time frame: day 1 to up to 30 days (Hospital discharge)
Hospitalization duration and treatment cost due to AECOPD as primary cause
Time frame: day 1 to up to 30 days (Hospital discharge)
Percentage of treatment category before AECOPD and at discharge
Time frame: day 1 to up to 30 days (Hospital discharge)
Clinical efficacy and safety within different administration route of corticosteroid treatment
Time frame: day 1 to up to 30 days (Hospital discharge)
Demographic data
Time frame: day 1
Year of COPD diagnosis
Time frame: day 1
Any other significant medical condition or co-morbidities
Time frame: day 1
Smoking status (number of pack-years)
Time frame: day 1
Onset date of this AECOPD, date of hospitalization, date of discharge
Time frame: day 1 to up to 30 days (Hospital discharge)
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca